Moreover, recent preclinical studies suggest that CDK4/6 blockade may be particularly effective in MMR-deficient (dMMR) tumors, in part due to its immunomodulatory potential.27 Additional studies are needed to determine if dMMR/hypermutator recurrent oligodendrogliomas may benefit from CDK4/6 inhibition. This evidence concerns the gene CDK4 and oligodendroglioma.